Asset Details
Do you wish to reserve the book?
Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome
Do you wish to request the book?
Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome
2025
Overview
This article reports a rare case of a patient with POEMS syndrome who developed secondary myelodysplastic syndrome (MDS) two years after undergoing autologous stem cell transplantation (ASCT). The patient was initially misdiagnosed with chronic inflammatory demyelinating polyneuropathy (CIDP) due to symptoms of limb numbness and weakness. Two years later, the diagnosis was corrected to POEMS syndrome. After induction therapy with the lenalidomide-dexamethasone (RD) regimen, ASCT is performed and partial remission is achieved. And lenalidomide was used for maintenance therapy. Over a year later, he was infected with SARS-CoV-2 and subsequently developed pancytopenia. Bone marrow routine revealed increased myeloblasts with multilineage dysplasia, and next-generation sequencing (NGS) found a TP53 mutation, leading to the diagnosis of secondary MDS. The pathogenesis of secondary MDS in POEMS syndrome is discussed from three aspects: cytotoxic therapy, genetic predisposition, and SARS-CoV-2 infection. This case underscores the importance of prolonged surveillance for secondary myeloid neoplasms (sMN) in POEMS patients and suggests that early genomic profiling and individualized treatment may improve outcomes.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ autologous stem cell transplantation
/ Blood
/ Dexamethasone - therapeutic use
/ Disease
/ Hematopoietic Stem Cell Transplantation - adverse effects
/ Humans
/ Lenalidomide - therapeutic use
/ Male
/ Mutation
/ Myelodysplastic Syndromes - diagnosis
/ Myelodysplastic Syndromes - etiology
/ Plasma
/ POEMS Syndrome - complications
/ Proteins
/ Severe acute respiratory syndrome coronavirus 2
/ Tumor Suppressor Protein p53 - genetics
/ Tumors
